Quarterly report pursuant to Section 13 or 15(d)

Organization and Principal Activities - Additional Information (Details)

v3.23.1
Organization and Principal Activities - Additional Information (Details)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
USD ($)
Segment
shares
Mar. 31, 2022
USD ($)
Dec. 31, 2022
USD ($)
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Date of incorporation Apr. 21, 2003    
Headquartered in South San Francisco    
Headquartered in state CA    
Number of operating segments | Segment 1    
Accumulated deficit $ 502,665   $ 452,615
Unrestricted cash, cash equivalents and marketable securities $ 251,500    
Substantial doubt about going concern, within one year false    
Underwriting discounts and commissions and other offering expenses   $ 22  
Vaxcyte      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Unrestricted cash, cash equivalents and equity securities at carrying value $ 25,000    
At-the-Market (“ATM") | Common Stock      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Shares of common stock | shares 1,641,374    
Gross proceeds from issuance of common stock $ 11,200    
Underwriting discounts and commissions and other offering expenses 300    
Net proceeds from issuance of common stock $ 10,900    
Minimum      
Organization Consolidation And Presentation Of Financial Statements [Line Items]      
Period from issuance date of unaudited interim condensed financial statements 12 months